Research analysts who have asked questions during KAMADA earnings calls.
Annabel Samimy
Stifel Financial Corp.
6 questions for KMDA
Also covers: ALT, APLS, CARA +14 more
James Sidoti
Sidoti & Company
2 questions for KMDA
Also covers: ANIK, ASRT, GAIA +10 more
Jim Sidoti
Sidoti & Company, LLC
2 questions for KMDA
Also covers: ANIK, GAIA, GOCO +4 more
AP
Anthony Petrone
Mizuho Group
1 question for KMDA
Also covers: ADMA, ALC, BSX +22 more
Recent press releases and 8-K filings for KMDA.
Kamada Provides 2026 Annual Guidance and Affirms 2025 Financial Guidance
KMDA
Guidance Update
Revenue Acceleration/Inflection
Earnings
- Kamada Ltd. provided its 2026 annual guidance, forecasting revenues between $200 million and $205 million and adjusted EBITDA between $50 million and $53 million.
- The company affirmed its 2025 financial guidance, expecting revenues of $178 million to $182 million and adjusted EBITDA of $40 million to $44 million, with approximately $75 million in year-end cash as of December 31, 2025.
- The 2026 midpoint guidance represents a year-over-year increase of 13% in revenues and 23% in adjusted EBITDA compared to the mid-points of the 2025 guidance, driven solely by continued organic growth.
- Expected growth in 2026 is anticipated from the expansion of its commercial product portfolio, including increased U.S. sales, and continued sales growth of KAMRAB®, GLASSIA®, HEPAGAM®, and VARIZIG® in ex-U.S. markets.
- The company also expects growth from its Distribution segment through new biosimilar product launches in Israel and expansion into the MENA region, as well as initial sales of normal source plasma.
Jan 7, 2026, 12:00 PM
Kamada Provides 2026 Guidance and Affirms 2025 Financial Outlook
KMDA
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Kamada announced 2026 annual guidance, projecting revenues between $200 million and $205 million and adjusted EBITDA between $50 million and $53 million, driven solely by organic growth.
- This 2026 guidance represents a year-over-year increase of 13% in revenues and 23% in adjusted EBITDA at the mid-points, compared to 2025 guidance.
- The company affirmed its 2025 financial guidance of $178 million - $182 million in revenues and $40 million - $44 million of adjusted EBITDA, with an anticipated 2025 year-end cash of approximately $75 million.
- Kamada is also focused on securing new business development and M&A transactions to further accelerate long-term profitable growth.
Jan 7, 2026, 12:00 PM
Kamada Announces Extension of Canadian Supply Tender and Reaffirms 2025 Guidance
KMDA
Guidance Update
New Projects/Investments
- Kamada Ltd. has been awarded a $10-$14 million extension to an existing tender from Canadian Blood Services (CBS) for the supply of four specialty plasma-derived products.
- This extension secures ongoing sales of approximately $5.0-$7.0 million per year for the period between Q2 2026 and Q1 2028.
- The company reiterated its 2025 full-year revenue guidance of $178 million-$182 million and adjusted EBITDA guidance of $40 million-$44 million.
- Kamada projects double-digit growth in revenues and profitability in 2026.
Dec 18, 2025, 12:00 PM
Kamada Announces Extension of Canadian Supply Tender and Reaffirms 2025 Guidance
KMDA
Guidance Update
New Projects/Investments
- Kamada has been awarded a $10-$14 million extension to an existing supply tender from Canadian Blood Services for four specialty plasma-derived products, securing ongoing sales of approximately $5.0-$7.0 million per year between Q2 2026 and Q1 2028.
- The company reiterated its 2025 full-year revenue guidance of $178 million-$182 million and adjusted EBITDA guidance of $40 million-$44 million.
- Kamada projects double-digit growth in revenues and profitability in 2026.
Dec 18, 2025, 12:00 PM
Kamada Discontinues Phase 3 Inhaled AAT InnovAATe Clinical Trial
KMDA
Guidance Update
New Projects/Investments
- Kamada announced the discontinuation of its Phase 3 inhaled AAT InnovAATe clinical trial due to futility, as an independent data safety monitoring board (DSMB) determined it was unlikely to achieve its primary endpoint.
- The decision was based on the limited likelihood of efficacy and was not related to any safety concerns.
- Despite the trial discontinuation, Kamada is on track to meet its full-year 2025 revenue guidance of between $178 million-$182 million and annual Adjusted EBITDA of between $40 million-$44 million.
- The company projects double-digit growth in revenues and profitability for 2026 and expects to eliminate annual study costs of $5-$6 million associated with the trial after early 2026, which are anticipated to flow through to the bottom line.
Dec 8, 2025, 1:30 PM
Kamada Discontinues Phase 3 Clinical Trial, Reaffirms Financial Guidance
KMDA
Guidance Update
New Projects/Investments
- Kamada has discontinued its Phase 3 Inhaled AAT InnovAATe clinical trial due to futility, as an independent Data Safety Monitoring Board (DSMB) advised it was unlikely to demonstrate a statistically significant benefit in its primary endpoint of lung function.
- The decision was based on efficacy, not safety concerns, and Kamada remains committed to the Alpha-1 community through its continued supply of GLASSIA.
- Despite the trial discontinuation, Kamada reaffirmed its full year 2025 revenue guidance of between $178 million-$182 million and annual Adjusted EBITDA guidance of between $40 million-$44 million.
- The company projects double-digit growth in revenues and profitability for 2026, benefiting from the elimination of $5-$6 million in annual study costs after early 2026, which are expected to fall directly to the bottom line.
Dec 8, 2025, 1:30 PM
Kamada Discontinues Phase 3 Trial, Reaffirms 2025 Guidance, and Projects 2026 Growth
KMDA
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Kamada has discontinued its Phase 3 inhaled AAT InnovAATe clinical trial due to futility, as an independent Data Safety Monitoring Board (DSMB) advised it was unlikely to demonstrate statistically significant benefit in its primary endpoint of lung function.
- The decision was based on efficacy and not related to safety concerns; Kamada remains committed to the Alpha-1 community through its Glassia product.
- Despite the trial discontinuation, Kamada is on track to meet its full-year 2025 revenue guidance of $178 million-$182 million and annual Adjusted EBITDA of $40 million-$44 million.
- The company projects double-digit growth in revenues and profitability for 2026 and anticipates eliminating $5-$6 million in annual study costs from the discontinued trial, which will directly benefit the bottom line after early 2026 closure activities.
Dec 8, 2025, 1:30 PM
KAMADA Provides 2025 Guidance and Reports Strong 9M/25 Financial Results
KMDA
Guidance Update
Earnings
New Projects/Investments
- Kamada projects 2025 revenues between $178 million and $182 million and Adjusted EBITDA between $40 million and $44 million.
- For the nine months ended September 30, 2025 (9M/25), total revenues increased 11% year-over-year to $135.8 million, and Adjusted EBITDA rose 35% year-over-year to $34.2 million.
- The company maintained a strong cash position of $72.0 million as of September 30, 2025.
- Growth is driven by four key pillars: the Inhaled AAT Pivotal Study, expansion of plasma collection centers, M&A transactions, and organic growth.
- Kamada's portfolio includes six FDA-approved specialty plasma products, with GLASSIA® generating $17 million in 2024 royalty income and CYTOGAM® contributing $23 million in 2024 revenues.
Nov 24, 2025, 12:00 PM
Kamada Provides Business Update and Growth Strategy at Stifel Healthcare Conference
KMDA
Guidance Update
New Projects/Investments
M&A
- Kamada reported over 30% growth in Q3 and is on track to meet its 2025 guidance of $178-$182 million in revenue and $40-$44 million in EBITDA.
- The company is actively pursuing M&A opportunities, aiming to finalize a transaction in the coming months to accelerate growth from 2026, supported by $72 million in cash and a $40 million credit line.
- New plasma collection centers are expected to contribute an additional $8-$10 million in annual revenue per center from normal-source plasma sales starting early next year.
- Kamada's inhaled AATD program, in a pivotal Phase 3 study, anticipates a futility analysis by year-end 2025, targeting a $2 billion market opportunity upon potential completion of the study by 2029.
Nov 12, 2025, 2:20 PM
Kamada Reports Strong Q3 2025 Results and Reaffirms Full-Year Guidance
KMDA
Earnings
Guidance Update
New Projects/Investments
- Kamada reported total revenues of $47 million for the third quarter of 2025, a 13% increase compared to Q3 2024, and $135.8 million for the first nine months of 2025, an 11% increase year-over-year.
- Net income for Q3 2025 was $5.3 million, or $0.09 per diluted share, up 37% compared to Q3 2024. Adjusted EBITDA for Q3 2025 was $11.7 million, up 34% over Q3 2024.
- The company reiterated its annual revenue guidance of $178 million-$182 million and adjusted EBITDA guidance of $40 million-$44 million for 2025.
- The Houston plasma facility received FDA approval, and the San Antonio site is expected to follow in early 2026. The pivotal phase 3 inhaled AAT program is on track to complete an interim futility analysis by the end of Q4 2025.
- Kamada expects to secure compelling in-licensing, collaboration, and/or M&A transactions during early 2026.
Nov 10, 2025, 1:30 PM
Quarterly earnings call transcripts for KAMADA.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more